Alcon Inc. - Registered Shares
ALC
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
May 6, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
32.2% upsideUndervalued by 32.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $32.58 Billion |
|---|---|
| Enterprise Value | $36.29 Billion |
| Dividend Yield | $0.36 (0.54%) |
| Earnings per Share | $1.99 |
| Beta | 0.7 |
| Outstanding Shares | 487,200,000 |
Return
| Return on Equity | 3.66% |
|---|---|
| Return on Assets | 2.56% |
| Return on Invested Capital | 3.23% |
Valuation & Multiples
| P/E Ratio | 39.95 |
|---|---|
| PEG | -84.9 |
| Price to Sales | 3.18 |
| Price to Book Ratio | 1.49 |
| Enterprise Value to Revenue | 3.43 |
| Enterprise Value to EBIT | 39.09 |
| Enterprise Value to Net Income | 44 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.5234▲ 102.25% |
|---|---|
| Total Calls | 3,710,035▼ 72.52% |
| Total Puts | 5,652,000▼ 16.43% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 46.72%▼ 2.86% |
|---|---|
| Total Invested | $17.08B▼ 11.53% |
| Investors Holding | 680▼ 2.00% |
ESG Score
No data
About Alcon, Inc.
20,000 employees
CEO: David J. Endicott Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the followi...
Relevant Senate Committees
This committee provides the official revenue estimates and technical analysis for all tax legislation. Its reports directly inform and influence the tax-writing process, which determines corporate tax structures, deductions, and credits, thereby having a direct and significant impact on Alcon's financial planning and net profitability.
This powerful committee controls taxation, trade, and entitlement spending (like Medicare). Its decisions on corporate tax policy directly impact Alcon's profitability. Furthermore, its influence on Medicare pricing and reimbursement policies significantly affects the market for Alcon's surgical procedures and pharmaceutical products, as many patients are covered by Medicare.
This committee directly allocates discretionary federal spending. Its subcommittees determine precise funding for various federal programs, including those related to healthcare (e.g., NIH research, VA healthcare funding, Medicare/Medicaid budgets), which directly impact the funding available for the purchase of Alcon's products and relevant research initiatives.
This committee directly regulates agencies vital to Alcon, such as the FDA (Food and Drug Administration), which approves Alcon's pharmaceutical eye drops, surgical devices, and contact lenses. Its oversight of NIH also impacts research funding relevant to eye care, making it a primary regulatory body for Alcon's products.
This committee oversees intellectual property (patents, trademarks), which is critical for protecting Alcon's pharmaceutical formulations and medical device designs. It also handles antitrust laws, impacting potential mergers, acquisitions, and competitive practices within Alcon's markets.
This committee's funding decisions directly impact the Department of Veterans Affairs, which is a major purchaser and provider of healthcare. Alcon's surgical equipment, devices, and pharmaceutical eye drops are highly relevant to the care provided to veterans, making this committee's actions directly influential on Alcon's sales to the VA.